EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer

Sreya Duttagupta, Taiki Hakozaki iD, Bertrand Routy, Meriem Messaoudene

Current Oncology · 2023

DOI: 10.3390/curroncol30110681 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2023. Verfasst von Sreya Duttagupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Montreal Research Centre (CRCHUM), Montreal, QC H2X 0A9, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Gastrointestinal Microbiome, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gastrointestinal microbiome has been shown to play a key role in determining the responses to cancer immunotherapy, including immune checkpoint inhibitor (ICI) therapy and CAR-T. In patients with non-small cell lung cancer (NSCLC), increasing evidence suggests that a microbiome composition signature is associated with clinical response to ICIs as well as with the development of immune-related adverse events. In support of this, antibiotic (ATB)-related dysbiosis has been consistently linked with the deleterious impact of ICI response, shortening the overall survival (OS) among patients on ATBs prior to ICI initiation. In parallel, several preclinical experiments have unravelled various strategies using probiotics, prebiotics, diet, and fecal microbiota transplantation as new therapeutic tools to beneficially shift the microbiome and enhance ICI efficacy. These approaches are currently being evaluated in clinical trials and have achieved encouraging preliminary results. In this article, we reviewed the recent studies on the gut microbiome as a potential biomarker and an adjuvant therapy to ICIs in NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsGastrointestinal MicrobiomeCarcinoma, Non-Small-Cell LungHumansImmunotherapyBiomarkers

Stichwörter der Autor:innen

antibioticsdietfecal microbiota transplantationgut microbiomeimmune checkpoint inhibitorsnon-small cell lung cancerpolyphenolsprebioticsprobiotics

Substanzen

Biomarkers

Autor:innen und Institutionen

  • University of Montreal Research Centre (CRCHUM), Montreal, QC H2X 0A9, Canada.
  • Graduate School of Advanced Science and Engineering, Faculty of Science and Engineering, Waseda University, Tokyo 169-8050, Japan.
  • Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre, Montreal, QC H2X 3E4, Canada.

ORCID-Profile: Taiki Hakozaki

Zitieren

APA

Duttagupta, S., Hakozaki, T., Routy, B., & Messaoudene, M. (2023). The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer. Current Oncology. https://doi.org/10.3390/curroncol30110681

Vancouver

Duttagupta S, Hakozaki T, Routy B, Messaoudene M. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer. Current Oncology. 2023. doi:10.3390/curroncol30110681

BibTeX
@article{Duttagupta2023,
  author = {Duttagupta, Sreya and Hakozaki, Taiki and Routy, Bertrand and Messaoudene, Meriem},
  title = {The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30110681}
}
Kostenlos starten →